Triomune – Lamivudine + Stavudinde Tablet
Description
Lamivudine + Stavudinde (Triomune) Tablet – Treatment for HIV Infection
Triomune 30mg/40mg Tablet is an antiretroviral medication combination. It is given to those who have HIV (human immunodeficiency virus). It improves immunity to fight HIV in order to manage or cure AIDS (acquired immunodeficiency syndrome).
Triomune 30mg/40mg Tablet keeps HIV at bay by inhibiting the virus from replicating in the body. It also improves the function of your immune system and may reduce your risk of getting HIV-related diseases such as AIDS. This guarantees that you will live a long and healthy life. To get the most out of your medication, avoid missing doses and carefully follow your doctor’s recommendations. Taking Triomune Tablet, as well as practicing safer sex and adopting other lifestyle changes, may reduce the chance of HIV virus transmission to others.
Triomune Tablet inhibits the growth of HIV in the body and lowers the risk of HIV-related diseases, hence increasing an individual’s lifespan. For maximum efficacy, the medication should be taken on an empty stomach. Taking these medications on a daily basis boosts their efficacy. This medication should not be skipped since it may have an impact on your recovery. It is important to finish the entire course of treatment until your doctor tells you to discontinue it.
Fedelty Health Care is a certified Lamivudine + Stavudinde Bulk Pharma Exporter, Cargo Bulk Supplier, and pharmaceutical wholesaler in India.
USES OF LAMIVUDINE + STAVUDINDE (TRIOMUNE) 30MG/40MG TABLET
- HIV infection
WORKS OF LAMIVUDINE + STAVUDINDE (TRIOMUNE) 30MG/40MG TABLET
Triomune Tablet contains three antiviral medications: Lamivudine, Stavudine, and Nevirapine. They function by blocking HIV (virus) replication, lowering the amount of virus in your body. They also raise the number of CD4 cells (white blood cells that fight infection) in your blood.
DIRECTIONS FOR USE:
Take this medication at the dose and for the length of time prescribed by your doctor. Swallow it fully. Do not eat, crush, or break it. Triomune Tablet should be taken on an empty stomach.
Fedelty Health Care is a certified Lamivudine + Stavudinde Bulk Pharma Exporter, Cargo Bulk Supplier, and pharmaceutical wholesaler in India.
SIDE EFFECTS OF LAMIVUDINE + STAVUDINDE (TRIOMUNE) 30MG/40MG TABLET
- Headache
- Tiredness
- Insomnia (difficulty in sleeping)
- Nausea
- Diarrhea
- Dryness in mouth
- Fever
- Rash
- Peripheral neuropathy
WARNING & PRECAUTIONS
- Driving
Triomune Tablet may induce negative effects that impair your driving abilities. You may feel tired when using Triomune Tablet, which may impair your ability to drive.
- Kidney
Triomune In people with renal illness, the tablet should be taken with caution. Triomune Tablet dosage may need to be adjusted. Please visit your physician.
- Liver
In people with liver illness, Triomune Tablet is probably safe to use. Based on the current data, it appears that no dosage change of Triomune Tablet is required in these individuals. Please visit your physician.
Inform your doctor if you experience any jaundice symptoms while taking Triomune Tablet. You may need to discontinue the use of this medication.
- Pregnancy
Triomune tablets may be harmful if used while pregnant. Although there has been little human research, animal studies have revealed detrimental consequences on the growing fetus. Before prescribing it to you, your doctor will consider the advantages as well as any possible hazards. Please visit your physician.
- Breastfeeding
Triomune Tablet is most likely safe to use during nursing. According to the limited human evidence, the medication poses no major harm to the fetus.
Fedelty Health Care is a Lamivudine + Stavudinde third-party manufacturer, bulk pharma exporter, and pharmaceutical contract manufacturer operating businesses in Venezuela, Saudi Arabia, Cambodia, Oman, Brazil, Lebanon, Chile, Peru, Cuba, and Fiji. Other services they provide are hospital supply, government supply, named patient supply, cold chain supply, and drop shipping.
